Emerging anticoagulant and thrombolytic drugs

Bibliography

• COLMAN RW, HIRSH J, MARDER V, SALZMAN EW: Haemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, USA (1994).
   Google Scholar
• BLOOM AL, THOMAS DP: Haemostasis and thrombosis. Churchill Livingstone, New York, USA (1994).
   Google Scholar
• LOSCALZO J, SCHAFER AT: Thrombosis and haemor-rhage. Blackwell, Boston, USA (1994):1–1337.
   Google Scholar
• Virchow R (Ed.), Von Meidinger Sohn, Frankfurt, Germany (1856):458–636.
   Google Scholar
• Verstraete M, Fuster V, Topol EJ (Eds.), Lipincott-Raven Publishers, Philadelphia, USA (1998):3–22.
   Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ, CHESEBRO JH: The pathogenesis of coronary artery disease and acute coronary syndrome. N Engl..) Med. (1992) 326:310–318.
   PubMed Web of Science ®Google Scholar
• FURIE B, FURIE BC: Molecular and cellular biology of blood coagulation. N Engl. J. Med. (1992) 326:800–806.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, NAKAGAKI T, KISIEL W: Tissue factor dependent autoactivation of human blood coagulation factor. J. Biol. Chem. (1992) 267:19089–19094.
   PubMed Web of Science ®Google Scholar
• WICOX JN, SMITH KM, SCHWARTZ SM, GORDON D: localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA (1989) 86:2839–2843.
   PubMed Web of Science ®Google Scholar
• DRAKE TA, MORRISSEY JH, EDGINGTON TS: Selective cellular expression of tissue factor in human tissues. Am. J. Pathol. (1989) 134:1087–1097.
   PubMed Web of Science ®Google Scholar
• TEITEL JM, ROSENBERG RD: Protection of Factor Xa from neutralization by heparin antithrombin complex. J. Clin. Invest. (1983) 71:1383–1391.
   PubMed Web of Science ®Google Scholar
• MILETICH JP, JACKSON CM, MAJERUS PW: Properties ofFactor Xa binding site on platelets. J Biochem. (1978) 253:6908–6916.
   Google Scholar
• WEITZ JI: Iipw molecular weight heparins. N Engl. J.Med. (1997) 337:688–698.
   PubMed Web of Science ®Google Scholar
• RIVERA TM, LEONE-BAY A, PATON DR, LEIPOLD HR, BAUGHMAN RA: Oral delivery of heparin in combina-tion with sodium N48-(2-hydroxybenzoyliamino) caprylate: pharmacological considerations. Pharm. Res. (1997) 14:1830–1834.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN RA, KAPOOR SC, AGARWAL RK, et al: Oraldelivery of anticoagulant doses of heparin. A random-ized, double-blind controlled study in humans. Circulation (1998) 98:1610–1615.
   PubMed Web of Science ®Google Scholar
• GONZE MD, MANORD JD, LEONE-BAY A, et al.: Orallyadministered heparin for preventing deep vein thrombosis. Am. J. Surg. (1998) 176:176–178.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON DM: Insight into the mechanism of actionof heparin cofactor II. Thromb. Haemost. (1995) 74:1209–1214.
   PubMed Web of Science ®Google Scholar
• DICARLO V, AGNELLI G, PRANDONI P, et al: Dermatansulfate for the prevention of postoperative venous thrombosis in patients with cancer. DOS (Dermatan Sulfate in Oncologic Surgery) Study Group. Thromb. Haemost. (1999) 82:30–34.
   PubMed Web of Science ®Google Scholar
• BUCHANAN MR, BRISTER SJ: Anticoagulant andantithrombin effects of intimatan, a heparin cofactor II agonist. Thromb. Res. (2000) 99:603–612.
   PubMed Web of Science ®Google Scholar
• HOPPENSTEADT D, RACANELLI A, WALENGA JM, FAREEDJ: Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Semin. Thromb. Haemost. (1992) 15:378–385.
   Web of Science ®Google Scholar
• Ofosu FA, Danishefsky I, Hirsh J (Eds.), The New York Academy of Sciences, NY, USA (1989):81–94.
   Google Scholar
• Ricci G et al. (Eds.), Raven Press, New York, USA (1982) :189–194.
   Google Scholar
• Poller L (Ed.), Churchill Livingstone, New York, USA (1993).
   Google Scholar
• ••Comprehensive coverage of non-heparin GAGs.
   Google Scholar
• AGRATI AM, DEBARTOLO G, PALMIERI G: Heparan sulfate: efficacy and safety in patients with chronic venous insufficiency. Minerva Cardioangiol. (1991) 39(10395–400.
   Google Scholar
• CARAMELLI L, MIRCHIONI R, CARINI: Effectiveness ofshort-term sulfoxide treatment on peripheral vascular disease clinical manifestations. Riv. Eur. Sci. Med. Farmacol (1988) 10(0:55–58.
   PubMedGoogle Scholar
• BERGQUIST D, KETTUNEN K, FREDIN H, et al.: Thrombo-prophylaxis in patients with hip fractures: A prospec-tive, randomized, comparative study between Org 10172 and dextran 70. Surgery (1991) 109(5):617–622.
   PubMed Web of Science ®Google Scholar
• ROMEO S, GRASSO A, COSTANZO C: A controlled clinical experiment 'within subjects' with heparan sulfate in intermittent claudication. Minerva Carioan-giol. (1991) 39(9):345–352.
   Google Scholar
• LANE DA, RYAN K, IRELAND H, et al: Dermatan sulfate inhemodialysis. Aus. NZ J. Med. (1991) 21 (1):52–54.
   PubMedGoogle Scholar
• CONFRANCESCO E, BOSCHETTI C, LEONARDI P, CORTELLARO M: Dermatan sulfate in acute leukemia. Lancet (1992) 339 (8802):1177–1178.
   Web of Science ®Google Scholar
• HOGG PJ, JACKSON CM: Fibrin monomer protectsthrombin from inactivation by heparin:antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. USA (1989) 86:3619–3623.
   PubMed Web of Science ®Google Scholar
• WEITZ JJ, HUDOBA M, MASSEL D, MARAGANORE J, HIRSHJ: Clot-bound thrombin is protected from inhibition by thrombin-antithrombin III but is susceptible to inacti-vation by antithrombin III-dependent inhibitors. J. Clin. Invest. (1990) 86:385–391.
   PubMed Web of Science ®Google Scholar
• WEITZ JJ, LESLIE B, HUDOBA M: Thrombin binds tosoluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation (1998) 97:544–552.
   PubMed Web of Science ®Google Scholar
• LANE DA, PEJLER J, FLYNN AM, THOMSON EA, LINDAHLU: Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4./ Biol. Chem. (1986) 261:3980–3986.
   PubMed Web of Science ®Google Scholar
• HARVEY RP, DEGRYSE E, STEFANI L, et al.: Cloning andexpression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalls. Proc. Natl. Acad. Sci. USA (1986) 83:1084–1088.
   PubMed Web of Science ®Google Scholar
• STONE SR, HOFSTEENGE J: Kinetics of inhibition of thrombin by hirudin. Biochemistry (1986) 25:4622–4628.
   PubMed Web of Science ®Google Scholar
• STRINGER KA, LINDENFELD J: Hirudins:antithrombotic anticoagulants. Ann. Pharmacother. (1992) 26:1535–1540.
   PubMed Web of Science ®Google Scholar
• SCHEIL F, VUILLEMENOT A, KRAMARZ P, et al.: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am. J. Haematol. 50:25–29 (1995).
   Google Scholar
• NAND S: Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am. Haematol. (1993) 43:310–311.
   PubMed Web of Science ®Google Scholar
• ORTEL TL, CHONG BH: New treatment options for heparin-induced thrombocytopenia. Semin. Haematol. (1998) 35:26–34.
   PubMed Web of Science ®Google Scholar
• RIESS FC, LOWER C, SEELIG C: recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J. Thorac. Cardiovasc. Surg. (1995) 110:265–267.
   PubMed Web of Science ®Google Scholar
• POTZSCH B, IVERSEN S, RIESS FC: Recombinant hirudin as an anticoagulant in open-heart surgery: a case report. Ann. Haematol. (1994) 68:A53.
   PubMed Web of Science ®Google Scholar
• ERICKSON BI, EKMAN S, KALEBO P, ZACHRISSON B, BACH D, CLOSE P: Prevention of deep vein thrombosis after total hip replacement: direct thrombin inhibi-tion with recombinant hirudin, CGP 39393. Lancet (1996) 347:635–639.
   PubMed Web of Science ®Google Scholar
• ERICKSON BI, WILLE-JORGENSENP, KALEBO P, et al.: A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl. J. Med. (1997) 337:1329–1335.
   PubMed Web of Science ®Google Scholar
• OASIS INVESTIGATORS: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation (1997) 96:769–777.
   PubMed Web of Science ®Google Scholar
• OASIS-2 INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared with heparin in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Lancet (1998) 353:429–448.
   Web of Science ®Google Scholar
• IQBAL O, GERDISCH MW, DAVALLE MJ, et al.: Successful use of recombinant hirudin for anticoagulation and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing cardiac bypass surgery (abstract). Session XVII: Perfusion/Cardiac Tumors. Cardiovasc. Engin. (2000) 5 (2):151.
   Google Scholar
• MARAGANORE JM, BOURDON P, JABLONSKI J, RAMACHANDRAN KL, FENTON JW: Design and charac-terization of hirulogs: a novel class of bivalent peptide inhibitors on thrombin. Biochemistry (1990) 29:7095–7101.
   PubMed Web of Science ®Google Scholar
• WITTING JI, BOURDON P, BREZNIAK DV, MARAGANOREJM, FENTON JW: Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochemistry (1992) 283 :737–743.
   Web of Science ®Google Scholar
• FOX I, DAWSON A, LOYNDS P, et al.: Anticoagulant activity of hirulog, a direct inhibitor of thrombin. Thromb. Haemost. (1993) 69:157–163.
   PubMed Web of Science ®Google Scholar
• MARAGANORE JM, ADELMAN BA: Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coronmy Arteiy Dis. (1996) 7:438–448.
   PubMed Web of Science ®Google Scholar
• BITTL JA, STRONY J, BRINKER JA, et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. Hirulog Angioplasty Study Investigators. N Engl. J. Med. (1995) 333:764–769.
   PubMed Web of Science ®Google Scholar
• BITTL JA, FEIT F: A randomized comparison of bivali-rudin and heparin in patients undergoing coronary angioplasty for post-infarction angina. Hirulog Angioplasty Study Investigators. Am. J. Cardiol (1998) 82: 43–49.
   Google Scholar
• THEROUX P, PEREZ-VILLA F, WATERS D, LESPERANCE J,SHABANI F, BONAN R: Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocar-dial infarction. Circulation (1995) 91:2132–2139.
   PubMed Web of Science ®Google Scholar
• FITZGERALD D, MURPHY N: Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coronmy Artely Dis. (1996) 7:455–458.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, MATTHAS W, GRASSMAN JD, et al.: Results of Phase 2/3 trial of argatroban anticoagulation during P'ILA of patients with heparin-induced thrombocy-to p en ia (HIT). Circulation (1997) 96:1-217 (Abstract).
   Google Scholar
• JANG IK:Arandomized study of argatroban vs.heparin as adjunctive therapy to tissue plasminogen activator in acute myocardial infarction: MINT (Myocardial Infarction with Novastan and tPAO Study. Circulation (1997) 96:1-331 (Abstract).
   Google Scholar
• ERICKSON UG, JOHANSON L, FRISON L, et al.: Single and repeated oral dosing of H376/95, a prodrug for the direct thrombin inhibitor, melagatran, to young healthy male subjects. Blood (1999) 94:26a (Abstract #101).
   Web of Science ®Google Scholar
• GUSTAFFSSON D, NYSTROM JE, CARLSSON S, et al.: Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor, melagatran, intended for oral use. Blood (1999) 94:26a (Abstract).
   Google Scholar
• BAJUSZ S, SZELL E, BADGY D, et al.: Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactiva-tion and its stable N-methyl derivative. J. Med. Chem. (1990) 33:1729–1735.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JW, MORRISON JF: The kinetics of reversibletight-binding inhibition. Methods Enzymol. (1979) 63:437–467.
   PubMedGoogle Scholar
• HILPERT K, ACKERMAN J, BANNER DW, et al: Design andsynthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. (1994) 37:3889–3901.
   PubMed Web of Science ®Google Scholar
• TEGER-NILSSON AC, ERICKSON U, GUSTAFSSON D, BYLUND R, FAGER G, HELD P: Phase I studies on inogatran, a new selective thrombin inhibitor. j Am. Coll Cardiol (1995) 23:117-118 (Abstract).
   Google Scholar
• BENEDICT CR, RYAN J, WOLITZKY B, et al.: Active-siteblocked Factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. j Clin. Invest. (1991) 88:1760–1765.
   PubMed Web of Science ®Google Scholar
• FUERSTEIN GZ, PATEL A, TOOMEY JR, et al.: Antithrom-botic efficacy of a novel murine antihuman Factor IX antibody in rats. Arterioscl Thromb. Vasc. Biol. (1999) 19:2554–2562.
   PubMed Web of Science ®Google Scholar
• FUERSTEIN GZ, TROOMEY JR, VALOCIK R, KOSTER P,PATEL A, BLACKBURN MN: An inhibitory antiFactor IX-antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb. Haemost. (1999) 82:1443–1450.
   PubMed Web of Science ®Google Scholar
• BAJAJ SP, RAPAPORT SI, MAKI SL: A monoclonalantibody to Factor IX that inhibits the Factor VIII:Ca potentiation of Factor X activation. j Biol. Chem. (1985) 260:11574–11580.
   PubMedGoogle Scholar
• HERBERT JM, HERAULT JP, BERNAT A, et al: Biochemicaland pharmacological properties of SANORG 34006, a potent and long acting synthetic pentasaccharide. Blood (1998) 91:4197–4205.
   PubMed Web of Science ®Google Scholar
• HIRSH J: Heparin. N Engl. J. Med. (1991) 324:1565–1574.
   PubMedGoogle Scholar
• VLASUK GP: Structural and functional characterization of a tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. (1993) 70:212–216.
   PubMed Web of Science ®Google Scholar
• CHOAY J, PETITOU M, LORMEAU JC, SINAY P, CASU B, GATTI G: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and aliciting high anti-Factor Xa activity. Biochem. Biophys. Acta (1983) 116:492–499.
   Google Scholar
• SINAY P, JAQUINET JE, PETITOU M, et al.: Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr. Res. (1984) 132:C5–C9.
   Web of Science ®Google Scholar
• PETITOU M, DUCHAAUSSOY P, LEDERMAN J, et al.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 0-(2-deoxy-2-sulfamido-6-0-sulfo-alpha-m-glucopyr an osyl)-1 4)-0-(beta-D-glucopyranosyluronic acid)-(14)-0-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-L-idopyranosyluronic acid)-(14)-2-deoxy-2-sulfamido-6-0-sulfo-D-glucop-yranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr. Res. (1986)147:221–236.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, PETITOU M, LORMEAU JC, SAMAMA M, FAREED J, CHOAY J: An tithr ombo tic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. (1987) 46:187–198.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, BARA L, PETITOU M, SAMAMA M, FAREED J, CHAOY J: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasac-charide with sole anti-Factor Xa activity. Thromb. Res. (1988) 51:23–33.
   PubMed Web of Science ®Google Scholar
• HOBBELLEN PMJ, VAN DINTHER TG, VOGEL GMT, VAN BOECKEL CAA, MOELKER HCT, MEEULEMAN DG: Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (Pentasaccharide) in rats. Thromb. Haemost. (1990) 63:265–270.
   PubMed Web of Science ®Google Scholar
• IQBAL O, DAUD AN, KIRSCHMAIER B, et al.: Heparinase neutralization of low molecular weight heparins. Turkish J. Haematol. (2000) 17 (Suppl. 3):102–137.
   Google Scholar
• TUSZYNSKI GP, GASIC TB, GASIC GJ: Isolation and characterization of antistatin. J. Biol. Chem. (1987) 262:9718–9723.
   PubMed Web of Science ®Google Scholar
• DUNWIDDIE CT, THORNBERRY NA, BULL HG, et al.: Antistatin, a leech-derived inhibitor of Factor Xa. Kinetic analysis of enzyme inhibition and identifica-tion of the reactive site. j Biol. Chem. (1989) 264:16694–16699.
   PubMed Web of Science ®Google Scholar
• RIGBI M, JACKSON CM,ATAMNA H, et al.: FXa inhibitorfrom the saliva of the leech Hirudo medicinalis. Thromb. Haemost. (1995) 73:1306.
   Google Scholar
• JORDAN SP, MAO SS, LEWIS SD, SHAFER JA: Reactionpathway for inhibition of blood coagulation Factor Xa by tick anticoagulant peptide. Biochemistry (1992) 31: 5374–5380.
   Google Scholar
• JORDAN SP, WAXMAN L, SMITH DE, VLASUK GP: Tick anticoagulant peptide:kinetic analysis of the recombi-nant inhibitor with blood coagulation Factor Xa. Biochemistry (1990) 29:11095–11100.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, DOL F, HERAULT JP, CREPON B,LORMEAU JC: DX-9065a, a novel, synthetic, selective and orally active inhibitor of Factor Xa: in vitro and in vivo studies. J. Pharmacol. Exper. Ther. (1996) 276:1030–1038.
   PubMed Web of Science ®Google Scholar
• TANIUCHI Y, SAKAI Y, HISAMICHI N, et al: Biochemicaland pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human Factor Xa. Thromb. HaemosL (1998) 79:543–548.
   PubMed Web of Science ®Google Scholar
• WONG PC, QUAN ML, CRAIN EJ, WATSON CA, WEXLER RR, KNABB RM: Nonpeptide Factor Xa inhibitors. I. Studies with SF303 and SK549, anew antithrombotic. Pharmacol. Exp. Ther. (2000) 292:351–357.
   PubMed Web of Science ®Google Scholar
• QUAN ML, ELLIS CD, LIAUW AY, et al.: Design and synthesis of isox azoline derivative as Factor Xa inhibi-tors. J. Med. Chem. (1999) 42:2760–2773.
   PubMed Web of Science ®Google Scholar
• FURIE B, BURIE BC: Molecular and cellular biology ofblood coagulation. N Engl. J. Med. (1992) 326:800–806.
   PubMed Web of Science ®Google Scholar
• BROZE GL JR, WARREN LA, NOVOTNY WF, et al.: Thelipoprotein-associated coagulation inhibitor that inhibits the Factor VII-tissue factor complex also inhibits Factor Xa: insight into the possible mechanism of action. Blood (1988) 71:335–343.
   PubMed Web of Science ®Google Scholar
• Vane JR, Born JVR, Welzel D (Eds.), FK Schattauer Verlagsgesselschaft, Stuttgart, Germany (1995):165–182.
   Google Scholar
• BECKER RC, SPENCER F, LI Y, et al: Thrombin generation after the abrupt cessation of intravenous unfraction-ated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J Am. Coll. Cardiol. (1999) 34:1020–1027.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor. Thromb.HaemosL (1995) 74:90–93.
   PubMed Web of Science ®Google Scholar
• CAPPELLO M, VLASUK GP, BERGUM PW, HUANG S, HOTEZ PJ: Ancylostoma caninum anticoagulant peptide: a hookworm derived inhibitor of human coagulation Factor Xa. Proc. Nati Acad. Sci. USA (1996) 93:2149–2154.
   PubMed Web of Science ®Google Scholar
• VLASU K, BERGUM PW, BRUNCK TK, et al.: Anticoagulantrepertoire of hematophagous nematodes. Throm. HaemosL (1995) 73:1305.
   Google Scholar
• ESMON NL, OWEN WG, ESMON CT: Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol. Chem. (1982) 257:859–864.
   PubMed Web of Science ®Google Scholar
• ESMON NL, CARROLL RC, ESMON CT: Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol. Chem. (1983) 258:12238–12242.
   PubMedGoogle Scholar
• ESMON CT: The roles of protein C and thrombo-modulin in the regulation of blood co ag-ulatio n Biol. Chem. (1989) 264:4743–4746.
   Google Scholar
• MARLAR RA, KLEISS AJ, GRIFFIN JH: Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 591: 1067–1072.
   Google Scholar
• SUZUKI K, KUSUMOTO H, DEYASHIKI Y, et al.: Structureand expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor of protein C activation. EMBO J. (1987). 6:1891–1897.
   PubMed Web of Science ®Google Scholar
• GOMI K, ZUSHI M, HONDA G, et al: Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood (1990) 75:1396–1399.
   PubMed Web of Science ®Google Scholar
• PARKINSON JF, GRINNEL BW, MOORE RE, HOSKINS J, VLAHOS CJ, BANG NU: Stable expression of a secretable deletion mutation and recombinant human thrombo-modulin in mammalian cells. J Biol. Chem. (1990) 265 :12602–12610.
   PubMed Web of Science ®Google Scholar
• ONO M, NAWA K, MARUMOTO Y: Antithrombotic effects of recombinant human soluble thrombo-modulin in a rat model of vascular shunt thrombosis. Thromb. HaemosL (1994) 72:421–425.
   PubMed Web of Science ®Google Scholar
• AOKI Y, OHISHI R, TAKEI R, et al.: Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb. HaemosL (1994) 71:452–455.
   PubMed Web of Science ®Google Scholar
• MARUYAMA I, SAITO H, MATSUDA T, AOKI N: Antithrombotic effect of recombinant soluble thrombomodulin on disseminated intravascular coagulation. Zimmerman Conference Proceedings (1996) 1:82 (Abstract).
   Google Scholar
• Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (Eds.), Churchill Livingstone, London, UK (1994):671–698.
   Google Scholar
• DAHLBACK B: protein S and c4b-binding protein. Components involved in the regulation of the protein C anticoagulant system. Thromb. HaemosL (1991) 66:49–61.
   PubMed Web of Science ®Google Scholar
• ESMON CT, DING W, YASUHIRO K, et al: The protein C pathway. Thromb. HaemosL (1997) 78:70–74.
   PubMed Web of Science ®Google Scholar
• GRINNELL BW, BERG DT, WALLS J, YAN SB: Trans-activated expression of fully 7-carboxylated recombi-nant human protein C, antithrombotic factor. Biotech-nology (1987) 5:1189–1192.
   Web of Science ®Google Scholar
• BAJZAR L, MORSER J, NESHEIM M: TAFI or plasma procarboxipeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin- thrombomodulin complex. J. Biol. Chem. (1996) 271:16603–16608.
   PubMed Web of Science ®Google Scholar
• SAKHAROV DV, PLOW EF, RIJKEN DC: On the mechanism of antifibrinolytic activity of plasma carboxypeptidase B. J. Biol. Chem. (1997) 272:14477–14482.
   PubMed Web of Science ®Google Scholar
• REDLITZ A, NICOLINI FA, MALYCKY JL, TOPOL EJ, PLOW EF: Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation (1996) 93:1328–1330.
   PubMed Web of Science ®Google Scholar
• KLEMENT P, LIAO P, BAJZR L: A novel approach to arterial thrombolysis. Blood (1999) 94:2735–2743.
   PubMed Web of Science ®Google Scholar
• MOSESSON MW: The roles of fibrinogen and fibrin in haemostasis and thrombosis. Semin. Hematol. (1992) 29:177–178.
   PubMedGoogle Scholar
• SEALE L, FINNEY S, SAWYER RT, WALLIS RB: Tridegin, a novel peptide inhibitor of Factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro. Throm. HaemosL (1997) 77:959–963.
   Google Scholar
• FINNEY S, SEALE L, SAWYER RT, WALLIS RB: Tridegin, a new peptide inhibitor of Factor XIIIa, from the blood sucking leech, Haementeria ghilianii. Biochem. J. (1997) 324:797–805.
   PubMed Web of Science ®Google Scholar
• BASKOVA IP, NIKONOV GI: Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity. Blood Coagul. Fibrinol. (1991) 2:167–172.
   PubMed Web of Science ®Google Scholar
• ZAVALOVA L, LUKYANOV S, BASKOVA I, et al.: Genes from the medicinal leech (Hrudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopep tide bonds and help to dissolve blood clots. Mol. Gen. Genet. (1996) 253:20–25.
   PubMedGoogle Scholar
• FUJII S, SAWA H, SOBEL BE: Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb. Haemost. (1993) 70:642–647.
   PubMed Web of Science ®Google Scholar
• BROWN SL, SOBEL BE, FUJII S: Attenuation of the synthesis of plasminogen activator inhibitor Type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation (1995) 92:767–772.
   PubMed Web of Science ®Google Scholar
• KVASSMAN J, LAWRENCE D, SHORE J: The acid stabiliza-tion of plasminogen activator inhibitor 1 depends on the protonation of a single group that affects loop insertion into I3-sheet A. J. Biol. Chem. (1995) 270:27942–27947.
   PubMed Web of Science ®Google Scholar
• EITZMAN DT, FAY WP, LAWRENCE DA, et al.: Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin. Invest. (1995) 95:2416–1420.
   PubMed Web of Science ®Google Scholar
• FREDERICH P, LEVI M, BIEMOND B, et al.: Novel low molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation (1997) 96:916–921.
   PubMed Web of Science ®Google Scholar
• COLLER BS, SCUDDER LE, BEER J, et al.: Monoclonal antibodies to platelet glycoprotein Hb/IIIa as antithrombotic agents. Ann. NY Acad. Sci. (1991) 61 4:193–213.
   Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIbillIa receptor in high risk coronary angioplasty: the EPIC Investigators. N Engl. J Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein Hb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization: the EPILOG Investigators. N. Engl. J. Med. (19 9 7) 336:1689-1696.
   Google Scholar
• LINCOFF AM, CALIFF RM, MOLITERNO DJ, et al.: Comple-mentary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein receptors. Evaluation of platelet IIbillIa inhibition in Stenting Investigators. N. Engl. J. Med. (1999) 341:319–327.
   PubMed Web of Science ®Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein Hb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIbillIa in unstable angina: receptor suppression using integrelin therapy. N Engl. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• ••Excellent article on inhibition of glycoprotein IIb/IIIareceptors with eptifibatide in patients with ACS.
   Google Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOSM (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycopro-tein IIbillIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. N Engl. J. Med. (1998) 338:1488–1497.
   PubMed Web of Science ®Google Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGA-TORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl. J Med. (1998) 338:1498–14505.
   PubMed Web of Science ®Google Scholar
• CHEW D, BHATT D, TOPOL E: Increased mortality with oral platelet glycoprotein Hb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIbillIa trials. Am. J. Cardiol. (2000) 35:393A.
   Google Scholar
• TOPOL E: Toward a new frontier in myocardial reperfusion therapy: emerging platelet pre-eminence. Circulation (1998) 97:211–218.
   PubMed Web of Science ®Google Scholar
• COLLER BS: Platelet and thrombolytic therapy. N Engl. J. Med. (1990) 322:33–42.
   PubMed Web of Science ®Google Scholar
• GOLD H, COLLER B, YASUDA T, et al.: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GPIIbillIa antibody in a canine preparation. Circula-tion (1988) 77:670–677.
   PubMed Web of Science ®Google Scholar
• GOLD H, KEREIAKES D, DINSMORE R, et al.: A random-ized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: preliminary results. Circulation (1997) 96:1–474.
   Google Scholar
• ANTMAN E, GIUGLIANO R, GIBSON M, et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation (1999) 99:2720–2732.
   PubMed Web of Science ®Google Scholar
• ERIKSON BI, EKMAN S, KALEBO P, ZACHRISSON B, BACH D, CLOSE P: Prevention of deep vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet (1996) 347:635–639.
   PubMed Web of Science ®Google Scholar
• ERIKSON BI, WILLE-JORGENSONP, KALEBO P, et al: A comparison of recombinant hirudin with low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl. J. Med. (1997) 337:1329–1335.
   PubMed Web of Science ®Google Scholar
• IQBAL O, MESSMORE H, HOPPENSTEADT D, FAREED J, WEHRMACHER W: Thrombolytic drugs in acute myocardial infarction. Clin. Applied Thromb./Haemost. (2000) 6(0:1–13.
   PubMedGoogle Scholar
• IQBAL O, WALENGA JM, LEWIS BE, BAKHOS M: Bleeding complications with glycoprotein IIbillIa inhibitors. Drugs Today (2000) 36(8):503–514.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive coverage of bleeding complications withGPIIb/IIIa inhibitors.
   Google Scholar
• TURPIE G: The PENTATHLON 2000 Study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replace-ment surgery. Blood (2000) 96(11). Abstract #2112.
   Web of Science ®Google Scholar
• ••Comparison of the first synthetic Factor Xa inhibitor withLMWH in the prevention of VTE after elective hip replace-ment surgery.
   Google Scholar
• LASSEN MR: The EPHESUS Study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (IMW11). The prevention of venous thromboembolism (VTE) after elective hip replace-ment surgery. Blood (2000) 96(11). Abstract #2109.
   Google Scholar
• ERICKSON B: ThePENTHIFRAStudy: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (IMW11). The prevention of venous thromboembolism (VTE) after hip fracture surgery. Blood (2000) 96(11) Abstract #2110.
   Google Scholar
• BAUER K: The PENTAMAKS Study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin. The prevention of venous thromboembolism (VTE) after elective major knee surgery. Blood (2000) 96(11) Abstract #2111.
   PubMed Web of Science ®Google Scholar
• TURPIE AGG, GALLUS AS, HOEK JA FOR THE PENTASAC-CHARIDE INVESTIGATORS: A synthetic pentasaccha-ride for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med. (2001) 344(9)619–625.
   PubMedGoogle Scholar
• ••Excellent study on synthetic pentasaccharide for the preven-tion of DVT.
   Google Scholar
• FAREED J, HOPPENSTEADT D, BICK RL: New antithrom-botic drugs: a perspective. CUIT. Opin. Cardiovasc., Pulmon. Renal Invest. Drugs (1999) 40–46.
   Google Scholar
• BERNARD GR, VINCENT JL, LATERRE PF, et al. FOR THE RECOMBINANT HUMAN ACTIVATED PROTEIN C WORLDWIDE EVALUATION IN SEVERE SEPSIS (PROWESS) STUDY GROUP: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med. (2001) 344 (10) :699–709.
   PubMed Web of Science ®Google Scholar
• BAJAJ MS, TYSON DR, STEER SA, KUPPUSWAMY: Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells. Thrombosis Res. (2001) 101:203–211.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, HIRSH J: New anticoagulant drugs. Chest (2001)119:95S–107S.
   Google Scholar
• HIRSH J, DALEN JE, GUYATT G: The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. Chest (2001) 119:1S–2S.
   Google Scholar